Balaji Healthline

Ketorolac Tromethamine Injection is a non-steroidal anti-inflammatory drug (NSAID) used for the short-term management of moderate to severe pain, typically in a hospital or clinical setting. It works by inhibiting the enzymes COX-1 and COX-2, which are involved in the production of prostaglandins—chemicals responsible for pain, inflammation, and fever. Ketorolac provides potent analgesic and anti-inflammatory effects without the sedative or addictive properties of opioids, making it useful after surgeries or for acute pain conditions. Often administered via intramuscular or intravenous injection, it is usually given for no more than five days due to the risk of gastrointestinal, renal, and bleeding complications associated with prolonged use.

Prednisolone Tablets 20 mg are commonly formulated in combination with other supportive agents to enhance anti-inflammatory, immunosuppressive, or symptomatic relief effects depending on the clinical indication. These combinations may include antibiotics, antihistamines, or bronchodilators in respiratory conditions, or immunomodulatory agents in autoimmune or allergic disorders. Prednisolone, a synthetic glucocorticoid, works by suppressing inflammation and immune responses, making it valuable in treating a wide range of conditions such as asthma, rheumatoid arthritis, and severe allergies. The combination enhances therapeutic efficacy while potentially minimizing the required corticosteroid dose, thereby reducing the risk of steroid-associated side effects.

Pirfenidone 200 mg tablet is an anti-fibrotic and anti-inflammatory medication primarily used in the treatment of idiopathic pulmonary fibrosis (IPF), a chronic and progressive lung disease characterized by scarring of lung tissue. Each tablet contains 200 mg of pirfenidone as the active ingredient, which works by reducing the production of fibrotic and inflammatory mediators such as transforming growth factor-beta (TGF-β) and tumor necrosis factor-alpha (TNF-α). This helps slow down the progression of lung fibrosis and preserve lung function. Pirfenidone is not a combination drug—it contains a single active component—and is typically prescribed as part of a long-term treatment regimen. The tablets are usually taken orally with food to minimize gastrointestinal side effects.

Ketorolac Tablets 10 mg are a potent nonsteroidal anti-inflammatory drug (NSAID) used primarily for the short-term management of moderate to severe pain. Often formulated in combination with other analgesics or adjunct ingredients to enhance its pain-relieving effect, it may be paired with agents such as paracetamol (acetaminophen) or muscle relaxants in some formulations. Ketorolac works by inhibiting the cyclooxygenase (COX) enzymes, which are involved in the production of prostaglandins—substances that cause inflammation, pain, and fever. The combination aims to provide synergistic pain relief while potentially reducing the required dose of each component, thereby minimizing side effects. However, due to the risk of gastrointestinal, renal, and cardiovascular adverse effects, Ketorolac combinations are typically recommended for short-term use, usually not exceeding 5 days.

Pirfenidone Tablets 400 mg are commonly used in the treatment of idiopathic pulmonary fibrosis (IPF), a condition that causes progressive scarring of the lungs. These tablets may be formulated in combination with other supportive agents such as N-acetylcysteine, which acts as a mucolytic and antioxidant to help reduce oxidative stress in lung tissues. In some treatment protocols, Pirfenidone may also be used alongside bronchodilators or corticosteroids, depending on the patient’s symptoms and physician recommendations. The primary action of Pirfenidone is anti-fibrotic and anti-inflammatory, helping to slow disease progression by reducing fibroblast proliferation and the production of fibrogenic mediators such as transforming growth factor-beta (TGF-β). When used in combination therapy, it aims to enhance lung function preservation and improve overall respiratory outcomes in patients with fibrotic lung diseases.